These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 23246389)
1. Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. Butler J; Subacius H; Vaduganathan M; Fonarow GC; Ambrosy AP; Konstam MA; Maggioni A; Mentz RJ; Swedberg K; Zannad F; Gheorghiade M; J Am Coll Cardiol; 2013 Feb; 61(5):571-9. PubMed ID: 23246389 [TBL] [Abstract][Full Text] [Related]
2. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. Blair JE; Zannad F; Konstam MA; Cook T; Traver B; Burnett JC; Grinfeld L; Krasa H; Maggioni AP; Orlandi C; Swedberg K; Udelson JE; Zimmer C; Gheorghiade M; J Am Coll Cardiol; 2008 Nov; 52(20):1640-8. PubMed ID: 18992654 [TBL] [Abstract][Full Text] [Related]
3. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825 [TBL] [Abstract][Full Text] [Related]
4. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial). Shah AN; Mentz RJ; Gheorghiade M; Kwasny MJ; Fought AJ; Zannad F; Swedberg K; Maggioni AP; Konstam MA Am J Cardiol; 2012 Dec; 110(12):1803-8. PubMed ID: 22999071 [TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). Wong CM; Hawkins NM; Jhund PS; MacDonald MR; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Petrie MC; McMurray JJ J Am Coll Cardiol; 2013 Nov; 62(20):1845-54. PubMed ID: 23850914 [TBL] [Abstract][Full Text] [Related]
6. Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). Greene SJ; Hernandez AF; Sun JL; Metra M; Butler J; Ambrosy AP; Ezekowitz JA; Starling RC; Teerlink JR; Schulte PJ; Voors AA; Armstrong PW; O'Connor CM; Mentz RJ Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27623769 [TBL] [Abstract][Full Text] [Related]
7. Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Vaduganathan M; Ambrosy AP; Greene SJ; Mentz RJ; Subacius HP; Maggioni AP; Swedberg K; Nodari S; Zannad F; Konstam MA; Butler J; Gheorghiade M; Circ Heart Fail; 2012 Nov; 5(6):750-8. PubMed ID: 23051949 [TBL] [Abstract][Full Text] [Related]
8. Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial. Payvar S; Spertus JA; Miller AB; Casscells SW; Pang PS; Zannad F; Swedberg K; Maggioni AP; Reid KJ; Gheorghiade M; Eur J Heart Fail; 2013 Dec; 15(12):1382-9. PubMed ID: 23858000 [TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. Greene SJ; Vaduganathan M; Wilcox JE; Harinstein ME; Maggioni AP; Subacius H; Zannad F; Konstam MA; Chioncel O; Yancy CW; Swedberg K; Butler J; Bonow RO; Gheorghiade M; JACC Heart Fail; 2013 Dec; 1(6):488-96. PubMed ID: 24622000 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Greene SJ; Harinstein ME; Vaduganathan M; Subačius H; Konstam MA; Zannad F; Maggioni AP; Swedberg K; Butler J; Gheorghiade M; Am J Cardiol; 2012 Dec; 110(11):1657-62. PubMed ID: 22917555 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Greene SJ; Vaduganathan M; Lupi L; Ambrosy AP; Mentz RJ; Konstam MA; Nodari S; Subacius HP; Fonarow GC; Bonow RO; Gheorghiade M; Am J Cardiol; 2013 Feb; 111(4):574-81. PubMed ID: 23206923 [TBL] [Abstract][Full Text] [Related]
13. Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. Metra M; Davison BA; Gimpelewicz C; Carubelli V; Felker GM; Filippatos G; Greenberg BH; Hua TA; Liu Z; Pang PS; Ponikowski P; Severin TM; Voors AA; Wang Y; Cotter G; Teerlink JR Int J Cardiol; 2018 Feb; 253():91-96. PubMed ID: 29306479 [TBL] [Abstract][Full Text] [Related]
14. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. Mentz RJ; Chung MJ; Gheorghiade M; Pang PS; Kwasny MJ; Ambrosy AP; Vaduganathan M; O'Connor CM; Swedberg K; Zannad F; Konstam MA; Maggioni AP Am Heart J; 2012 Dec; 164(6):884-92.e2. PubMed ID: 23194489 [TBL] [Abstract][Full Text] [Related]
15. EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan. Cavalcante JL; Khan S; Gheorghiade M Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1331-8. PubMed ID: 19018685 [TBL] [Abstract][Full Text] [Related]
16. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Lanfear DE; Sabbah HN; Goldsmith SR; Greene SJ; Ambrosy AP; Fought AJ; Kwasny MJ; Swedberg K; Yancy CW; Konstam MA; Maggioni AP; Zannad F; Gheorghiade M; Circ Heart Fail; 2013 Jan; 6(1):47-52. PubMed ID: 23239836 [TBL] [Abstract][Full Text] [Related]
17. International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. Bhatt AS; Luo N; Solomon N; Pagidipati NJ; Ambrosio G; Green JB; McGuire DK; Standl E; Cornel JH; Halvorsen S; Lopes RD; White HD; Holman RR; Peterson ED; Mentz RJ; Am Heart J; 2019 Dec; 218():57-65. PubMed ID: 31707329 [TBL] [Abstract][Full Text] [Related]
18. Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial. Greene SJ; Fonarow GC; Solomon SD; Subacius H; Maggioni AP; Böhm M; Lewis EF; Zannad F; Gheorghiade M; Eur J Heart Fail; 2015 Jun; 17(6):591-600. PubMed ID: 25930208 [TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). Vaduganathan M; Dei Cas A; Mentz RJ; Greene SJ; Khan S; Subacius HP; Chioncel O; Maggioni AP; Konstam MA; Senni M; Fonarow GC; Butler J; Gheorghiade M; Am J Cardiol; 2014 Sep; 114(5):743-50. PubMed ID: 25060414 [TBL] [Abstract][Full Text] [Related]
20. Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). Khan SS; Campia U; Chioncel O; Zannad F; Rossignol P; Maggioni AP; Swedberg K; Konstam MA; Senni M; Nodari S; Vaduganathan M; Subacius H; Butler J; Gheorghiade M; Am J Cardiol; 2015 Mar; 115(6):790-6. PubMed ID: 25728846 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]